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Abstract: Lesion or disease of the somatosensory system leads to the development of neuropathic
pain. Peripheral neuropathic pain encompasses damage or injury of the peripheral nervous system.
On the other hand, 10–15% of individuals suffer from acute postoperative pain followed by persistent
pain after undergoing surgeries. Antidepressants, anticonvulsants, baclofen, and clonidine are used to
treat peripheral neuropathy, whereas opioids are used to treat postoperative pain. The negative effects
associated with these drugs emphasize the search for alternative therapeutics with better efficacy
and fewer side effects. Curcumin, a polyphenol isolated from the roots of Curcuma longa, possesses
antibacterial, antioxidant, and anti-inflammatory properties. Furthermore, the low bioavailability
and fast metabolism of curcumin have led to the advent of various curcumin formulations. The
present review provides a comprehensive analysis on the effects of curcumin and its formulations
in preclinical and clinical studies of neuropathic and postoperative pain. Based on the positive
outcomes from both preclinical and clinical studies, curcumin holds the promise of mitigating or
preventing neuropathic and postoperative pain conditions. However, more clinical studies with
improved curcumin formulations are required to involve its use as adjuvant to neuropathic and
postoperative drugs.
Keywords: curcumin; curcumin formulations; diabetes; peripheral neuropathy; postoperative pain;
preemptive analgesia
1. Introduction
Neuropathic pain has been defined as a process occurring after a primary lesion or
the disease of the somatosensory nervous system [1]. Based on either clinical examination
or self-reporting, the prevalence of neuropathic pain is 9.8% and 12.4%, respectively, in the
United States. However, due to differences in defining neuropathic pain, and employing
different epidemiological assessment methods, it is difficult to provide the accurate esti-
mate of neuropathic pain [2]. Peripheral neuropathic pain refers to damage or injury to
the peripheral nerves [3]. According to the Special Interest Group on Neuropathic Pain,
gabapentinoids, tricyclic antidepressants, and selective serotonin–norepinephrine reup-
take inhibitors have been identified as the first-line drugs for neuropathic pain, whereas
lidocaine, capsaicin, and tramadol are considered second-line drugs. Opioids such as
morphine, oxycodone, and botulinum toxin-A are included as third-line treatments for
peripheral neuropathic pain [4]. However, these drugs are accompanied by several side
effects that limit their use in preventing or treating neuropathic pain [4].
On the other hand, acute postoperative pain is followed by persistent pain in 10–15%
individuals undergoing surgeries, such as breast, bypass, and thoracic surgery, coronary,
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groin hernia repair, and leg amputation [5]. Opioids are effectively used to treat postopera-
tive pain [6]. However, prolonged use of opioids for chronic postoperative pain treatment
is less efficacious and is associated with major side effects, such as addiction, dependence,
liability, and opioid-induced hyperalgesia, nausea, vomiting, pruritus, and bowel motility
reduction leading to ileus and constipation [7–10].
Taken together, the negative side effects associated with neuropathic and postoperative
pain treatment reinforce the recommendations of evidence-based alternative therapeu-
tics to treat these aforementioned pain conditions. Natural products, including herbals,
flavonoids, and polyphenols, remain one of the most promising treatments for neuro-
pathic [11–16] and postoperative pain [17,18]. Curcumin, also known as diferuloylmethane,
is a polyphenolic compound present in the rhizomes of Curcuma longa (syn. C. domestica
Valeton and C. brog Valeton) (Zingiberaceae) used as a culinary spice in curry powder [19].
The antioxidant and anti-inflammatory properties of curcumin [20,21] could be attributed
to its antinociceptive activity against different pain conditions, including peripheral neuro-
pathic, inflammatory, postoperative, burn pain, and wound healing [22–25], as well as its
use as an oral supplement in the treatment of various inflammatory medical conditions,
such as alopecia [26].
Different curcumin formulations have been employed in order to improve the bioavail-
ability mainly by providing protection against chemical degradation of curcumin [27–34].
These formulations include encapsulation technologies of curcumin into nanoparticles or
microparticles and introduced in food or supplemental products [35]. Furthermore, the dif-
ferent colloidal particles that are used to incorporate curcumin include micellar aggregates,
biopolymer particles, emulsion droplets, liposomes, and solid lipid particles [36].
The present review provides insights into the analgesic effects of curcumin and its
formulations in neuropathic and postoperative pain conditions and explores its limitations
in preclinical and clinical studies. To the best of our knowledge, this is the first comprehen-
sive review that provides in-depth insights into the effects of curcumin and its different
formulations on behavioral, electrophysiological, and molecular aspects of both peripheral
neuropathic and postoperative pain.
2. Materials and Methods
The literature search mainly focused on the effects of curcumin and its different for-
mulations on preclinical studies, especially in rodent models of peripheral neuropathic and
postoperative pain conditions. However, a part of the review also presented the effects of
curcumin and its formulations in clinical studies of neuropathic and postoperative pain.
Outcome measures of interest were different behavioral modalities, such as mechanical,
thermal (heat and cold), motor coordination, electrophysiological parameters, and molecu-
lar markers of antioxidative enzymes, reactive oxygen species (ROS), inflammation, and
many more. All searches were conducted in PubMed and Google Scholar, and articles
published between 2010 and 2021 were selected for the review. Key search terms were
“curcumin”, “curcumin formulations”, “curcumin and peripheral neuropathic pain”, “cur-
cumin and postoperative pain”, “curcumin bioavailability”, “curcumin and neuropathic
and clinical studies”, and “curcumin and postoperative pain and clinical studies”.
3. Structure, Source, Metabolism, and Bioavailability of Curcumin
3.1. Chemical Structure
Structurally, the chemical skeleton of curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione] possesses different functional moieties that are bonded to two
phenol rings [37]. Two sets of α- and β-unsaturated carbonyl moieties link the phenol
rings [38,39], responsible for reaction with biological nucleophiles by employing Michael
addition and C-C adducts [40,41]. Furthermore, the chemical structure of curcumin contains
two methoxy aryl moieties at the ortho positions, a hydroxy substituent, and conjugated
β-diketone moieties [41]. Curcumin exists in two different tautomeric forms: 1,3-diketo
and enol forms [42,43] (Figure 1).
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3.2. Source and Metabolism
The genus Curcuma is widely cultivated in tropical and sub-tropical regions of Asia,
Australia, and South A erica [44]. Curcumin is obtained from the tuberous rhizomes
of C. longa, which is known as “turmeric” worldwide. C. longa is widely cultivated in
India, China, and Indonesia [19,45]. The active components of Curcuma rhizomes in-
volve volatile oils and nonvolatile curcuminoids (curcumin, demethoxycurcumin, bis-
demethoxycurcumin), which are nontoxic polyphenolic derivatives with several biological
activities [46,47]. Curcumin shows unfavorable pharmacokinetic properties (adsorption,
distribution, excretion, and metabolism), insolubility in aqueous solutions, instability
in neutral and alkaline pH, as well as sensitivity of both solid and solubilized forms to
light [48]. Curcumin metabolism mainly takes place in the liver, but also in the intestine by
gut microbiota [49]. It is rapidly etabolized either through the phase II conjugation of
curcumin-to-curcumin glucuronide and curcumin sulphate in the intestine and hepatic cy-
tosol or phase I enzymatic reduction of curcumin to dihydrocurcumin, tetrahydrocurcumin,
hexahydrocurcumin, and hexahydrocurcuminol in the enterocytes and hepatocytes [50–52].
Furthermore, glucuronidation occurs on reduced curcumin, leading to formation of cur-
cumin glucuronide, dihydro-curcumin-glucuronide, tetrahydrocurcumin-glucuronide, and
curcumin sulfate [50]. Dihy ro-ferulic acid and ferulic aci are also formed as the products
of secondary biliary metabolism [53,54] (Figure 2).
3.3. Bioavailability
Table 1 summarizes the serum and tissue levels of curcumin in rodents and humans
followed by different routes of administration. Despite its efficacy and safety, the poor
bioavailability of curcumin undermines its therapeutic potential. Animal studies reported
that oral administration [55,56] of curcumin led to its poor absorption, rapid metabolism,
and excretion. Oral consumption of curcumin leads to the rapid formation of conjugates,
such as curcumin glucuronide and curcumin sulfate in the small intestine, liver, and kid-
neys. The conjugates undergo rapid excretion in the urine and feces [50,57–62]. In humans,
curcumin has poor bioavailability, even when administered at a dose of 12 g/day [63].
Moreover, in humans, the oral bioavailability of curcumin is low because of its low ab-
sorption in the small intestine coupled to an extensive reduction and conjugation into
metabolites in the liver followed by elimination through the gall bladder [54,64].
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Table 1. Serum and tissue levels of curcumin in animal and clinical studies.
Animals Dose a, Route of Administration
Bioavailability
Reference
Tissue Concentration Time Measured afterAdministration
Animal Studies
NMRI and C57/BL6 mouse 50 mg/kg, force-fed Brain Below detection limit 30, 60, and 120 min
100 mg/kg, i.p. 0.004–0.005 mg/g 20–40 min [65]
C57BL6/J male and female
mice
0.148 mg, i.p. Brain
0.000739 ± 0.019 mg/g
2.010 µM 4 h [55]
Plasma 0.000127 ± 0.035 mg/mL0.345 µM
0.148 mg, oral Brain
0.000519 ± 0.098a mg/g
1.412 µM 4 h
Plasma Below detection level
0.074 mg, intramuscular Brain
0.001162 ± 0.004 mg/g
3.157 µM 4 h
Plasma 0.000238 ± 0.048 mg/mL0.647 µM
~2.5 mg/day, oral (500 ppm) Brain
0.000469 ± 0.220 mg/g
1.276 µM 4 months
Plasma 0.000035 ± 0.014 mg/mL0.095 µM
~10 mg/day, oral (2000 ppm) Brain
0.000525 ± 0.125 mg/g
1.428 µM 4 months
Plasma 0.000171 ± 0.019 mg/mL0.465 µM
Male Sprague-Dawley rats 500 mg/kg, oral Plasma 0.00006 ± 0.01 mg/mL 41.7 ± 5.4 min [56]
10 mg/kg, intravenous Plasma 0.00036 ± 0.05 mg/mL Not mentioned
Male Sprague-Dawley rats 1000 mg/kg, oral Plasma 15 ng/mL 50 min [66]
Female BALB/c mice 0.1 g/kg, i.p.
Brain 0.00041 ± 0.01 mg/g
1 h [50]
Intestine 0.11704 ± 6.86 mg/g
Kidneys 0.00751 ± 0.08 mg/g
Liver 0.0269 ± 2.58 mg/g
Plasma 0.0006 ± 0.03 mg/g
Spleen 0.02606 ± 1.06 mg/g
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Table 1. Cont.
Animals Dose a, Route of Administration
Bioavailability
Reference
Tissue Concentration Time Measured afterAdministration
Clinical Studies
Human 500–8000 mg/day, oral Serum
0.51 ± 0.11 µM
























Human 0.45–3.6 g, oral Plasma 11.1 ± 0.6 nmol/L 1 h [68]Under 3.6 g Urine 0.1–1.3 nmol/L
Human 2 or 4 g, oral Plasma 7 ng/mL 24 weeks [69]
Human 100 mg, oral Plasma 3.2 nM 2 h [70]
Human 8 g, oral Plasma 29 to 91 ng/mL 3 months [71]
a = Varies based on the studies mentioned in the table; i.p. = intraperitoneal.
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4. Curcumin and Neuropathic Pain—Preclinical Studies
4.1. Alcoholic Neuropathy
Chronic alcohol consumption leads to an array of neurological aberrations, including
cortical and motility dysfunction, delirium tremens, psychosis, peripheral polyneuropathy,
and Wernicke encephalopathy [72]. Direct toxicity to alcohol, family history of alcoholism,
malnutrition, and thiamine deficiency are associated with alcoholic neuropathy [73–76].
However, it is unclear which of the above factors induces neuropathy [77]. Moreover,
alcohol promotes oxidative stress by decreasing the endogenous concentrations of antiox-
idants, such as α-tocopherol, ascorbate, and vitamin E [78], generating ROS and lipid
peroxidation [79], and damaging DNA, cellular protein, and other signaling pathways that
regulate oxidative stress [78].
Table 2 summarizes the effects of curcumin on alcoholic neuropathy. Curcumin
reduced alcohol-induced mechanical and thermal (heat and cold) hypersensitivity, inhib-
ited the reduction in motor nerve conduction velocity (MNCV), reduced inflammatory
cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β), and
reduced DNA fragmentation [80]. Curcumin also exerts antioxidant properties by re-
ducing the levels of calcium, neural nitrite, and malondialdehyde (MDA), and restoring
glutathione (GSH) levels [80]. Curcumin has also revealed better efficacy in reducing
the alcohol-induced behavioral outcomes and inflammatory cytokines when compared
to the standard drug α-tocopherol [80]. Treatments with curcumin or sildenafil, a drug
that is reported to reduce neuropathic pain in rodent models [81,82], did not reduce the
alcohol-induced pain behaviors and did not alter oxidative stress biomarkers [83]. How-
ever, combined low doses of curcumin and sildenafil were effective in treating chronic
alcohol-induced neuropathic pain. The results confirm that low doses of curcumin and
sildenafil might have interacted synergistically to mitigate alcoholic neuropathy [83]. There-
fore, the drug–supplement association might provide a therapeutic advantage in treating
alcoholic neuropathy under clinical settings.
Int. J. Mol. Sci. 2021, 22, 4666 8 of 36
Table 2. Effects of curcumin on alcoholic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic painful neuropathy (DPN).








35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., twice daily), oral,
10 weeks + curcumin: 20, 40 and 80 mg/kg, oral, 10 weeks + 35%
(v/v) ethanol (10 g/kg), oral, 10 weeks
↑Mechanical hyperalgesia threshold
(Randall–Selitto paw pressure test)
↓Mechanical allodynia (von Frey hair test)
Thermal hyperalgesia (Tail immersion test)
X Reduction in
MNCV
↓MDA, neural nitrite, and total calcium content
↓ TNF-α and IL-1β
and DNA fragmentation in sciatic nerve
[80]
Combination Study
Wistar Albino rats of
either sex
Curcumin per se: 60 mg/kg, i.p. 10 weeks
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 weeks) +
curcumin (30 and 60 mg/kg, oral, 10 weeks)
Sildenafil per se:
10 mg/kg, i.p. 10 weeks
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 weeks)
+ sildenafil
(5 and 10 mg/kg, oral, 10 weeks)
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 weeks) +
curcumin (30 mg/kg, oral, 10 weeks) + sildenafil (5 mg/kg, oral,
10 weeks)
Combination
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Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Male Sprague-Dawley rats
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)
Curcumin (200 mg/kg/day, oral, 10 consecutive days)
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + curcumin (100 or
200 mg/kg/day, oral, 10 consecutive days)
Not tested Not tested
In spinal cord and sciatic nerve tissues:
↓ NF-κB and GFAP leve s
↓mRNA expressions of TNF-α, IL6, NF-κB, iNOS,
Bcl-2 and Bcl-xL
↑mRNA expression of Nrf2
↓mRNA expressions of caspase-3, p53, Apaf-1
↓mRNA expressions of autophagy related genes
LC3A, LC3B, and B clin-1
↓ Immunohistochemical expressions of 8-OHdG,
c spase-3 and LC3B
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalges  t reshold (Randall–
Selitto p w pressure test) 
↓  Mechanical allodynia (von Frey hair est) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83]
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Spinal cord and sciatic nerve histological
architecture and integrity with no sciatic nerve





Oxaliplatin (4 mg/kg, i.p., twice weekly for 4 weeks) + curcumin
(12.5, 25 and 50 mg/kg, oral, 4 weeks)
↑Mechanical (von Frey) threshold
↓ Cold allodynia (aceto e test)
↑MNCV and
SNCV
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improv d motor co rdination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MD  level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Injured spinal cord cells
↑ Levels of SOD, GSH-Px, and CAT in spinal cord
↓MDA level in spinal cord
X Protein expression of p-NF-κB/NF-κB in spinal
cord
↓ TNF-α, IL-6 and IL-1β levels in spinal cord
[85]
Female Wistar rats Cisplatin (2 mg/kg, i.p., twice a week for 5 weeks) +curcumin (200 mg/kg, oral, once daily for 5 weeks) ↓ Thermal hypoalgesia (hotplate test)
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis i  die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  M ch nical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




↑Myelin thickness in sciatic nerve
X Nuclear and nucleolar atrophy, loss of neurons in
L4 DRG
[86]
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Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Male Swiss Albino mice
Vincristine sulfate (0.1 mg/kg, i.p., once per day for
7 consecutive days) + curcumin (15, 30, 60 mg/kg/day, oral,
14 consecutive days)
↑ Thermal hyperalgesia (hotplate test)
↓ Thermal allodynia (cold plate test) and
mechanical hyperalgesia (pin prick test)
O Motor coordination (rotarod test)
O Acute phase of nociception (formalin test)





↓ Calcium level in sciatic nerve
↑ SOD activity in sciatic nerve
↑ Sciatic SOD, CAT, GPx, and GSH
↓ Levels of LPO and NO
[87]
Male Wistar rats
Oxaliplatin (4 mg/kg, i.p., twice
weekly for 4.5 weeks) + curcumin (10 mg/kg, oral, twice
weekly for 4.5 weeks)
Cisplatin (2 mg/kg, i.p., twice
weekly for 4.5 weeks) + curcumin (10 mg/kg, oral, twice
weekly for 4.5 weeks)
O Motor coordination (rotarod test), cold (cold
water tail flick test), mechanical (paw pressure
test), thermal (tail flick test) nociception
Not tested
↓ Plasma concentration of neurotensin
Co-treatment with oxaliplatin or cisplatin




Diabetic Painful Neuropathy (DPN)
Male Wistar rats Streptozotocin (STZ) (100 mg/kg, i.p.) + curcumin (100 mg/kg,oral, 6 weeks)
↑ Body weight, and kidney weight/body weight
↑ Thermal hyperalgesia (hotplate and tail flick
test) and mechanical allodynia (von Frey)
↓ FBG, TG, total cholesterol, LDL-C, total peroxide,
serum creatinine, and BUN
↑ HDL-C
↓ Renal ACE1
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), ral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
TNF-α and IL-10 in kidneys and sciatic nerves
[89]
Male Sprague-Dawley rats
a Animals with type 2 diabetes with diabetic neuropathic pain +
curcumin (100 mg/kg, i.p., 14 days)
↑Mechanical withdrawal threshold (von Frey)
and thermal withdrawal latency (heat stimulus)
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not test d 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-







Male Albino Wistar rats
STZ (60 mg/kg, i.p.) + acute or chronic curcumin
(50 mg/kg/day, i.p.)
Acute treatment: only 30 min prior to pain assessment
Chronic treatment: from 7th day till 21st day injected once a day
O Hyperglycemia
Chronic treatment X Weight loss
Chronic treatment ↑ Thermal hyperalgesia
(plantar test) and mechanical allodynia (von Frey)
Naloxone pre-treatment ↓ Anti-allodynic effect of
chronic curcumin
Not tested Not tested [91]
Male Sprague-Dawley rats STZ (60 mg/kg, i.p.) + curcumin (200 mg/kg, intragastric,14 days)
O Hyperglycemia and increased body weight
↑ Tactile allodynia (von Frey) Not tested
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 g/kg, i.p. 10 weeks 
35% (v/v) thanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Protein expressions of NADPH oxidase subunits
gp91phox and p47phox in spinal cord
↓ H2O2 and MDA in spinal cord




STZ (65 mg/kg, i.p.) + curcumin (60 mg/kg, oral, daily from day
3 to day 28)
↓ Hyperglycemia and body weight
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Alcoholic Neu opathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
The mal hyperalgesia (Hargreaves test) and
mechanical allodynia (von Frey)
Not tested ↓ Spinal TNF-α and TNF-α receptor 1 [93]
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Diabetic Painful Neuropathy (DPN)
Female
Wistar Albino rats
STZ (50 mg/kg, i.p.) + curcumin (60 mg/kg, oral, 21 days)
Non-diabetic rats + curcumin (60 mg/kg, oral, 21 days) Not tested Not tested
↓MDA, TOS, OSI, and NO in brain and sciatic
tissues
↑ TAS in brain and sciatic tissues
[94]
Male Albino mice of Laka
strain
STZ (200 mg/kg, i.p.) + curcumin (15, 30, and 60 mg/kg, oral,4th
8th week)
↓ Plasma glucose level
↑ Body weight
↑ Thermal hyperalgesia (tail immersion warm
water test and hotplate test)




STZ (45 mg/kg, i.p.) + gliclazide (10 mg/kg, oral, 5 weeks)
STZ (45 mg/kg, i.p.) + gliclazide
(10 mg/kg, oral, 5 weeks) + gabapentin (30 mg/kg, i.p., 5 weeks)
STZ (45 mg/kg, i.p.) + gliclazide (10 mg/kg, oral, 5 weeks) +
curcumin (100 mg/kg, oral, 5 weeks)
↑ Thermal hyperalgesia (hotplate and tail
flick test), and mechanical hyperalgesia (tail
pinch test)
Not tested
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
C-peptide level
↓ Total NO, serum TNF-α and MDA
[96]
Male Albino mice of Laka
strain
STZ (200 mg/kg, i.p.) + insulin (10 IU/kg, s.c., 8 weeks)
STZ (200 mg/kg, i.p.) + curcumin (60 mg/kg, oral, 8th weeks)
STZ (200 mg/kg, i.p.) + resveratrol (20 mg/kg, oral, 8th weeks)
Insulin (10 IU/
kg, s.c., 8 weeks) + curcumin (60 mg/kg, oral, 8th weeks)
Insulin (10 IU/
kg, s.c., 8 weeks) + resveratrol (20 mg/kg, oral, 8th weeks)
Insulin per se ↓ Blood glucose level and ↑
body weight
Curcumin or resveratrol per se ↓ Blood glucose
level and ↑ body weight
Combination treatment O blood glucose level
and body weight
Combination treatment ↑ thermal hyperalgesia
(tail immersion warm water test nd hotplate
test) threshold
Not tested
Combination treatment ↓ Serum TNF-α level
compared to its per se effects
Combination treatment ↓ Brain nitrite level
compared to its per se effects
[97]
Behavioral modalities are mentioned within parentheses. a = Induction of type 2 diabetes with diabetic neuropathic pain: one group of animals fed high fat–fructose diet (HFD) for eight weeks and
another group received normal feeding. After significant differences in insulin sensitivity index (ISI) were found between two groups, then the HFD group received streptozotocin (35 mg/kg, i.p.);
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heat allodynia (hotplate test), mechanical hyper-
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Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
=
improve/restore/regenerate/repair; ↑ = increase/elevate/upregulate; ↓ = decrease/reduce/attenuate/downregulate; O = no difference/no effects; X = blocked/inhibit/prevent; ACE1 = angiotensin converting
enzyme 1; BUN = blood urea nitrogen; CAT = catalase; CIPN = chemotherapy-induced peripheral neuropathy; DPN = diabetic painful neuropathy; DRG = dorsal root ganglion; FBG = fasting blood glucose;
GSH-Px or GPx = glutathione peroxidase; GSH; = glutathione; H2O2 = hydrogen peroxide; HDL-C = high-density lipoprotein cholesterol; IL-1β = interleukin-1β; IL-6 = interleukin 6; iNOS = inducible nitric
oxide synthase; i.p. = intraperitoneal; LC3B = light chain 3B; LDL-C = low-density lipoprotein cholesterol; LPO = lipid peroxidation; MDA = malondialdehyde; MNCV = motor nerve conduction velocity; mRNA
= messenger RNA; NADPH = nicotinamide adenine dinucleotide phosphate reduced form; NF-κB = nuclear factor kappa B; NO = nitric oxide; Nrf2 = nuclear factor erythroid 2–related factor 2; OSI = oxidative
stress index; SFI = sciatic functional index; SNCV = sensitive nerve conduction velocity; SOD = superoxide dismutase; TAS = total antioxidant status; TG = triglycerides; TNF-α = tumor necrosis factor alpha; TOS
= total oxidant status.
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4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
The treatment of cancer with different anticancer agents, including vinca alkaloids,
platinum drugs (cisplatin and oxaliplatin), taxanes, and other chemotherapeutic drugs,
leads to CIPN, which affects 30–40% of patients [98]. The symptoms of CIPN initiate
with the onset of chemotherapy and improve with the completion of the therapy. How-
ever, 25–30% patients experience pain or unpleasant paresthesia, which even persists after
chemotherapy completion [99]. Moreover, CIPN could potentially lead to a decrease in
the dose of chemotherapeutics, change to less effective agents, and even cause cessation
of the treatment [100]. In terms of cellular mechanisms, anticancer drugs paclitaxel, vin-
cristine, and oxaliplatin lead to mitochondrial damage of sensory neurons in the dorsal
root ganglion (DRG), leading to the increased production of ROS [101–104]. Chemotherapy
leads to the cellular respiration impairment and decreases the production of adenosine
triphosphate (ATP). Therefore, promoting mitochondrial respiration and restoring mi-
tochondrial bioenergetics provide protection against CIPN [105,106]. Furthermore, the
anticancer drug treatment leads to the reduction in antioxidative enzymes, such as su-
peroxide dismutase (SOD) and catalase (CAT), causing an imbalance between oxidant
and antioxidant molecules [101,104,107]. This imbalance promotes the cellular apoptotic
pathways, leading to degeneration of peripheral sensory fibers and other inflammatory
events [108,109]. Therefore, antioxidant therapy is considered as an effective treatment
against CIPN [110].
Table 2 summarizes the effects of curcumin on CIPN. Curcumin improved platinum
drug cisplatin or oxaliplatin-induced thermal (heat or cold) and mechanical hypersensi-
tivity [85–87], and formalin test [87] in various strains of rodent models. However, Al
Moundhri et al. [88] reported that curcumin could not attenuate cisplatin- or oxaliplatin-
induced painful behavioral outcomes. The study attributed a few factors, such as low
number of animals in each treatment group, administration of low concentration of cur-
cumin, and other unknown factors to this effect [88]. Curcumin also did not exert any
impairment of neuromuscular coordination, indicating that curcumin did not alter motor
coordination [88].
Electrophysiological parameters, such as MNCV and sensory nerve conduction ve-
locity (SNCV) provide important insights into the function of sciatic nerves, showing the
severity of nerve injury [111]. In rodents, curcumin increased both MNCV and SNCV,
showing its favorable effects on functional deficits caused by the platinum drugs [85,86].
Furthermore, curcumin attenuated alkaloid vincristine-induced sciatic functional loss by
increasing level of sciatic functional index (SFI) in male Swiss albino mice [87]. The re-
sults further confirm the protective effects of curcumin against chemotherapy-induced
neuropathy [87]. The improvement in histopathology of the sciatic nerve, blockade of
nuclear, nucleolar atrophy, and neuronal loss supported the protective effects of curcumin
against platinum-induced neurotoxicity [86,88]. Al Moundhri et al. [88] also explored co-
administration of curcumin with either oxaliplatin or cisplatin and reported an insignificant
reduction in the platinum concentration in the sciatic nerve. The result indicates an interest-
ing neuroprotective activity of curcumin in which concomitant treatment of curcumin did
not affect the therapeutic efficacy of platinum drugs [88]. However, more research must be
conducted to further confirm the neuroprotective and anticancer activities of curcumin. Al
Moundhri et al. [88] also reported that curcumin reduced oxaliplatin and cisplatin-induced
increase in plasma neurotensin, providing an insight into neurotensin quantification as
a biomarker of platinum-based drug neurotoxicity. Furthermore, curcumin exerted its
antinociceptive activity against CIPN by modulating several markers of oxidative stress,
antioxidant enzymes, and inflammatory cytokines [84,85,87]. Curcumin exerted higher
efficacy in decreasing oxidative stress markers and increasing the endogenous antioxidative
enzymes compared to standard drugs, including pregabalin selective Cav 2.2 (a2d subunit)
channel antagonist [87]. In summary, the antinociceptive activity of curcumin against CIPN
could be attributed to its multiple actions, including attenuating pain behaviors, increasing
MNCV, SNCV, and SFI, and suppressing inflammatory proteins and cytokines.
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4.3. Diabetic Painful Neuropathy (DPN)
According to a report by the Centers for Disease Control and Prevention, about
30.3 million people have diabetes, including 9.4% of adults [112]. In the United States, 50%
of diabetic patients [113,114] are affected by DPN. Burning, excruciating stabbing pain,
numbness, tingling sensation, paresthesia, and hyperesthesia coupled with the aching
of feet or hands are some distinguished characteristic features reported in patients with
DPN [115,116].
The effects of curcumin on DPN are summarized in Table 2. Curcumin received much
attention in treating DPN and its associated complications in rodent models due to its
relative safety and inexpensiveness [89–97]. Curcumin modulated STZ-induced changes in
body weights in two different ways, by either increasing the STZ-induced reduction in body
weight [89,95,97] or preventing/decreasing STZ-induced increase in body weight [91,93].
Hyperglycemia is the classical diagnostic marker in both type 1 and type 2 diabetes and
is the major cause of diabetic neuropathy [117]. Curcumin significantly reduced elevated
blood glucose levels in both mice and rat models of diabetes [93,95,97].
Pain-associated behaviors in diabetic animals are measured as exaggerated responses
to painful stimuli (hyperalgesia) or nocifensive responses to normally innocuous stimuli
(allodynia) [118]. Curcumin attenuated diabetes-induced thermal [89–91,93,95–97] and
mechanical [89–93,96] hypersensitivities. Furthermore, curcumin showed protective effects
against renal complications of diabetes as evidenced by a significant decrease in blood urea
nitrogen (BUN), creatinine, and renal angiotensin converting enzyme 1 (ACE1) [89], an
enzyme that is reported in many tissues, including kidneys and nerves [119]. The study
also compared the renal protective effects of curcumin with captopril, an ACE inhibitor
with antioxidant and anti-inflammatory properties [120]. However, captopril exerted
significantly higher protective effects against renal complications of diabetes than curcumin
did, which could be attributed to the more potent ACE inhibitory effects of captopril
than curcumin.
Oxidative stress and inflammation are the two major factors that contribute to the
pathophysiology of diabetes and its complications [121,122]. Curcumin ameliorated oxida-
tive stress in DPN models by increasing the key enzymes for antioxidant defense, such as
SOD [92], and by increasing total antioxidant capacity (TAS) [94]. TAS provides protection
from the neurological damage caused by diabetes-induced oxidative stress [123,124]. It
also provides important information on the total antioxidant content in a biological sys-
tem [123,124]. Curcumin also exerted its antioxidant properties by reducing or scavenging
several oxidative stress markers, such as the lipid peroxidation marker MDA [92,94,96],
hydrogen peroxide (H2O2) [92], nitric oxide (NO) [94–97], and oxidative stress index (OSI)
and total oxidant status (TOS) [94]. OSI and TOS indicate a total concentration of all free
radicals generated by diabetes-related oxidative damage [123,125]. Zhao et al. [92] reported
that curcumin ameliorated the protein expressions of nicotinamide adenine dinucleotide
phosphate reduced form (NADPH) oxidase subunits gp91phox and p47phox. The phospho-
rylation activates NADPH oxidases, leading to the generation of ROS, including H2O2.
Therefore, decreases in gp91phox and p47phox could lead to the decrease in oxidative
stress [126–129]. In addition, curcumin exerted its anti-inflammatory properties by de-
creasing the production of pro-inflammatory cytokine TNF-α [89,93,95–97] or its receptor 1
(TNF-α receptor 1) [93]. In comparison with a standard antioxidant apocynin, curcumin
demonstrated similar antioxidant activity against DPN [92] (Table 2).
4.4. Sciatic Nerve Chronic Constriction Injury (CCI)
Animal models of CCI are widely used to study peripheral neuropathic pain. The CCI
model of nerve injury possesses two components, inflammatory and nerve injuries, which
resemble the pain found in humans [130].
Table 3 summarizes the effects of curcumin on sciatic nerve CCI. Similar to other
neuropathic pain models, curcumin alleviated CCI-induced neuropathic pain behaviors,
including heat [131–135], mechanical [92,131–133,135,136], and cold [137] hypersensitiv-
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ities. However, Moini Zanjani et al. [137] reported that low doses (12.5 and 25 mg/kg)
of curcumin did not reduce pain behavior but induced mechanical allodynia. However,
a high dose (50 mg/kg) of curcumin reduced cold allodynia [137]. The results indicate
that different doses of curcumin are effective in alleviating CCI-induced pain behaviors.
Curcumin alleviated CCI-induced neuropathic pain by inhibiting the expression of nuclear
factor kappa B (NF-κB) in the spinal cord and reducing the expression of CX3C chemokine
receptor 1 (CX3CR1) in the dorsal spinal cord and DRG [131] as well as attenuating the mes-
senger RNA (mRNA) or protein expressions [135] of an important inflammatory mediator,
cyclooxygenase-2 (Cox-2) [138], and its serum level [137]. Cox-2 is constitutively expressed
in the dorsal horn of the spinal cord and is upregulated following injury, leading to the trans-
mission of nociceptive input [139,140]. Besides modulating Cox2, curcumin also reduces
the serum level of cortisol by inhibiting the upregulated expression of 11β-hydroxysteroid
dehydrogenase type I enzyme (11βHSD1) [132]. The 11βHSD1 is a key enzyme that con-
verts cortisone to cortisol in humans, and 11-dehydrocorticosterone to corticosterone in
rodents [141]. These glucocorticoids exert their effects through glucocorticoid receptors
that play important roles in the maintenance and development of neuropathic pain by
regulating the function and expression of N-methyl-D-aspartate receptor (NMDAR) [142].
Yu et al. [133] reported that curcumin exerted anti-allodynic activity by blocking the im-
munohistochemical and protein expressions of N-methyl-D-aspartate receptor subunit
NR1 (NMDAR NR1) in the spinal cord and DRG. However, Jeon et al. [136] reported
that curcumin did not change the protein expression of NR1 in DRG. This discrepancy
could be attributed to the dose and duration of curcumin treatment. Yu et al. employed
100 mg/kg of curcumin for 14 days [133], whereas Jeon et al. [136] used 50 mg/kg of
curcumin for 7 days in rats. The treatment for 7 days [136] was probably too short to
see the curcumin-induced changes at the central sensitization. Therefore, future studies
are required to examine the long-term treatment of curcumin on central sensitization in
rodent chronic neuropathic pain model. In addition, NMDAR-mediated activation of
brain-derived neurotrophic factor (BDNF) is associated with the enrichment of p300/CREB-
binding protein (CBP) at the BDNF gene promoter I [143]. Curcumin exerted its therapeutic
activity by downregulating the recruitment of p300/CBP and histone acetyltransferase
(HAT) (acetyl-Histone H3/acetyl-Histone H4) to the BDNF promoter [135]. Curcumin also
downregulated p300/CBP HAT activity-mediated gene expression of Cox-2 [135].
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Table 3. Effects of curcumin on sciatic nerve chronic constriction injury (CCI).




Behavioral Evaluation/Other Diabetic Histopathological/Biochemical/Molecular
Male Sprague-Dawley rats CCI + curcumin (100 mg/kg, peritoneal, 14 days)
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Mechanical allodynia (von Frey) and thermal
hyperalgesia (Hargreaves test)
X Immunohistochemical and prot in expressions of NMDAR-NR1 in
spinal cord and DRG [133]
Male Sprague-Dawley rats CCI + curcumin (100 mg/kg, i.p., 14 days)
↑ Thermal withdrawal latency (heat stimulus) 7 days after
surgery and mechanical withdrawal threshold (von Frey) 10
days after surgery
↓ NF-κB p65 pro ein expression in lumbar spi al cord and DRG 7 days
after surgery
↓ CX3CR1 positive expression in spinal dorsal horn and DRG 7 days
after surgery
[131]
Male Sprague-Dawley rats CCI + curcumin (100 mg/kg, peritoneal, 14 days)
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Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Thermal hyperalgesia (Hargreaves test) and paw
withdrawal mechanical threshold (von Frey) on day 14
↓ Serum cortisol concentration
X Upregulated expression of 11βHSD1 in spinal dorsal
horn and DRG
[132]
Male Wistar rats CCI + curcumin (12.5, 25 and 50 mg/kg, i.p., 7 days) O Mechanical allodynia (von Frey)High dose ↓ Cold allodynia (acetone test) High dose ↓ Serum concentration of cyclooxygenase 2 [137]
Male Sprague-Dawley rats CCI + curcumin (20, 40, or 60 mg/kg, i.p., 14 days) ↓ Thermal hyperalgesia (Hargreaves test) and mechanicalallodynia (von Frey)
↓ Recruitment of p300/CBP and etyl-histone H3/acetyl-histone H4 to
the promoter of BDNF and Cox-2 genes
↓mRNA and protein expressions of BDNF and Cox-2 in spinal cord
[135]
Male Sprague-Dawley rats CCI + curcumin (50 mg/kg, oral, 7 days) ↓Mechanical allodynia (von Frey) O Protein expressions of p-ERK, p-JNK, and p-NR1 in DRG [136]
Male C57BL/6J mice CCI + curcumin (5, 15 or 45 mg/kg, oral, twice perday f r 3 weeks)
Chronic treatment ↓Thermal hyperalgesia (hotplate) and
mechanical allodynia (von Frey)
Depletion of descending noradrenaline (NA) by 6-OHDA X
Mechanical allodynia, but not thermal hyperalgesia
Depletion of 5-HT by PCPA X thermal hyperalgesia but not
mechanical allodynia
Antagonists β-AR (propranolol) but not α-AR
(phentolamine) X Mechanical allodynia
β2-AR (ICI 118,551) X Mechanical allodynia
5-HT1A (WAY-100635) X Thermal hyperalgesia
Antagonists Delta-opioid (naltrindole hydrochloride) ↓
Mechanical allodynia
Mu-opioid (β-funaltrexamine) X Thermal hyperalgesia
Kappa-opioid (nor-binaltorphimine) O Mechanical
allodynia or thermal hyperalgesia
Chronic treatment inc eased spin l monoamine serotonin and its
metabolite MHPG
Did not alter other monoamines/




CCI + curcumin (100 mg/kg, oral, 14 days)
CCI + tramadol (10 mg/kg, i.p., 14 days)
CCI + chronic constriction release (CCR) + curcumin
(100 mg/kg, oral, 14 days)
CCI + CCR + tramadol (10 mg/kg, i.p., 14 days)
CCI + curcumin (100 mg/kg, oral, 14 days) +
tramadol (10 mg/kg, i.p., 14 days)
CCI + tramadol, and CCI + CCR + tramadol ↑ Thermal
hyperalgesia (heat stimulus)
CCI + tramadol, and CCI + CCR + tramadol ↑Mechanical
allodynia (dynamic plantar test)
O Cold-induced pain (cold plate test)
↓ Sciatic and DRG TNF-α in CCI + CCR + tramadol
↑ Sciatic IL-10 in CCI + CCR + tramadol, whereas ↑ DRG IL-10 in CCI +
tramadol followed by CCI + CCR + tramadol
↑ Number of regenerated axons in CCI + CCR + curcumin and CCI +
CCR + tramadol
[144]
Behavioral modalities are mentioned within parentheses.
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35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
= improve;
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) et -
no  ( g/kg), oral, 10 weeks 
↑  Mechanical yperalgesi  threshold (Randall–
Selitto paw pressure test) 
↓  Mech nical allodynia (von Frey hair test) 
Thermal hyperalg sia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wi tar Albino rats
of either sex 
Curcu in per se: 6  mg/ g, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
 mg/ g, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 w eks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafi  (5 mg/kg, oral, 10 weeks) 
Co bination ✓ Impr ved motor coordination 
(rotarod test)  
↓  Therm l y eralg ia (hot l te test) and paw 
hea  a lodynia (hotpl te test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalge a (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
S hw nn cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
I  spin l ord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6 NF κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
= improve; ↓ = decrease/reduce; O = no effects; X = abolish/abrogate/block; BDNF = brain-derived neurotrophic factor; 11βHSD1 =
11β-hydroxystero d dehydrogenase type I enzyme; CBP = CREB-binding protein; CCI = chronic constriction injury; CCR = chronic constriction release; Cox-2 = cyclooxygenase-2; CX3CR1 = CX3C chemokine
receptor 1; DRG = dorsal root ganglion; i.p. = intraperitoneal; mRNA = m ss nger RNA; NF-κB = nucle r factor kappa B; NMDAR NR1 = N-methyl-D- spartate ec ptor subunit NR1; TNF-α = tumor necrosis
factor alpha.
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Curcumin turned out to be less efficacious in a chronic constriction injury-chronic
constriction release (CCI-CCR) model of neuropathic pain when compared to a neuropathic
drug tramadol hydrochloride, a synthetic opioid from the aminocyclohexanol group [145].
However, curcumin was effective in inducing high regeneration and decreasing degenera-
tion of nerve tissues in CCR compared to tramadol [144]. Findings from Ceyhan et al. [144]
indicate that long-term use of curcumin in surgical constriction release may exert beneficial
effects in ameliorating CCI-induced neuropathic pain.
Zhao et al. [134] explored the underlying mechanisms of antinociceptive action of cur-
cumin in CCI-induced neuropathic pain. The study proposed that descending monoamine
system spinal beta2-ARs and delta opioid receptors maintain the anti-allodynic activity of
curcumin on mechanical stimuli, whereas descending serotonergic system coupled with
spinal 5-HT1A receptors and mu opioid receptors are required for the anti-hyperalgesic
activity of curcumin on thermal stimuli [134].
4.5. Other Peripheral Neuropathic Pain Models
4.5.1. Sciatic Nerve Crush (SNC) Injury
Compression, fracture, crush, wound, and laceration lead to the injury of sciatic
nerves [146,147], and to the partial or total autonomic, motor, and sensory function
loss [148]. A sciatic nerve crush model in rodents is widely used to represent axonotmesis-
like moderate peripheral neuropathy (PN) injury and is characterized by myelin sheath
destruction and Wallerian degeneration [149].
Table 4 summarizes the effects of curcumin on SNC. Curcumin demonstrated neuro-
protective effects on peripheral nerve injury by promoting nerve regeneration [150–152]
and protecting the injured DRG and sciatic nerve structures [153,154]. In a combination
study, curcumin was administered with melatonin, a drug that is used in nerve tissue
recovery and repair [155]. Since melatonin is affected by light and dark, the study compar-
atively evaluated the effects of curcumin and melatonin in light and dark periods [156].
The results showed that curcumin exerted better efficacy in stimulating nerve regeneration
compared to melatonin. However, the effects of curcumin did not differ between the light
and dark periods of treatments, but melatonin showed significantly better efficacy in the
dark compared to light group [151]. Therefore, future studies should explore the effects
of curcumin in human nerve regeneration. Furthermore, Ma et al. [152] reported that
high doses of curcumin (100 mg/kg and 300 mg/kg) induced similar nerve regeneration
effects as mecobalamin, a neuroprotective agent commonly used as a neuroprotective
agent against neurodegenerative diseases [157]. All the evidence reinforces the neuro-
protective effects of curcumin in promoting nerve regeneration and accelerating motor
functional recovery.
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Table 4. Effects of curcumin on sciatic nerve crush injury (SNC), spared nerve injury (SNI), and sciatic nerve ligation (SNL).







Sciatic Nerve Crush (SNC) Injury
Male Sprague-Dawley rats
SNC + curcumin dissolved in polyethylene
glycol 300 at a concentration of
0.035 mg/µL, 0.2 mg/day osmotic
minipump infusion, 28 days
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Mechanical (von Frey), finger
spacing of injured paw (visual
static sciatic index), skillful
walking (beam walking task test),
grip strength (grip strength test)
↑MNCV and SNCV
↑Myelin sheath thickness




↑ Transcription factor Nrf2 expression
[150]
Female Wistar Albino rats SNC + curcumin (100 mg/kg, nasogastrictube, 28 days) Not tested
↑ SFI values
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice da ly), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 we ks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Amplitu e values an latency time
O G strocnemius muscle weight
O G ratios
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Male Wistar rats 
35% (v/v) et ol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  
and DNA fragmentation in sciatic 
nerve 
[80] 
Combi ation Study 
Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 g/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (a etone 
, tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Myelin thickness, axon diameter, and
nerve diameter
[154]
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, or l, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 week  
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcu in (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 g/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved otor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hy er-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓   expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
NCV, CMAP latency onset and
peak amplitude
↓ Atrophy of gastrocnemius muscle
↑Number of fluoro-gold-positive neurons
↑ Number of myelinated axons per nerve
transverse section and mean di met r of
nerve fibers
[152]
Female Sprague-Dawley rats SNC + curcumin (100 mg/kg, gavage,28 days) Not tested Not tested
↓ Decreased olume of ganglion, mean
cell volume, total volume of DRG cells (A-
and B-cells), total surface of DRG cells,





SNC + curcumin (100 mg/kg, i.p., 4 weeks)
+ melatonin (10 mg/kg, i.p., 4 weeks)
during light (9 am) and dark (9 pm) periods
Not tested
Light and dark curcumin
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M le Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 eeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil p r se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 a d 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
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Male Wistar r ts 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 eeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Im roved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mR A expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
SFI
Light and dark curcumin O Ampli udes
and conduction latencies of evoked
CMAP rec rd d in gastrocnemius muscle
Curcumin
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Male Wist r rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 g/kg, oral, 10 eeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Ran all–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail im ersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/k , twice daily, oral, 10 
eeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[8 ] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alcoholic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), an  diabetic painful neuropathy (DPN). 
Animals (Sex,
Strain)  
Dose (mg/kg), Route of Administration, Du-








Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Co bination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotpla  test) and paw 
he t allodynia (hotpla  test), mechanical hyper-
algesia (pin prick test), cold allodyni  (acetone 
tes ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




Light and dark curcumin
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An mals (Sex, 
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A coholic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i. ., 
twice daily), oral, 10 w eks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mecha ical hype algesia hr hold (Randall–
Selitto paw p essure test) 
↓  Mechanical allodynia (von Frey hair t st) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium ontent  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, ral, 10 
weeks) + 
curcumin (3 and 60 mg/kg, oral, 10 w eks)  
S lden fil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v v) eth no  ( g/ g, twice daily, or l, 10 
eeks) + sildenafil  
(5 and 10 mg/kg oral, 10 weeks)  
35% v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyper lgesia (hotplat  t st) and paw 
heat allodyni  (hotp ate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail c ld-hy eralgesia (tail imm sion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Eth nol- nduced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, or l, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, i OS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alcoholic n u pathy, chemoth rapy-induced peripheral neuropathy (CIPN), an  diabetic painful neuropathy (DPN). 
A imals (Sex, 
Stra n)  
Dose (mg/kg), Route of Administration, Du-








Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) thanol 10 g kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mecha ical hype algesia hreshold (Randall–
Sel tto paw pres ur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium ontent  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, or l, 10 
weeks) + 
curcumin (3 and 60 mg/kg, oral, 10 w eks)  
S l en fil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v v) eth nol (10 g/ g, twice daily, or l, 10 
eks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg oral, 10 weeks) 
Comb nati n ✓ Improve  motor coordination 
(rotarod test)  
↓  Therma  hyperalgesia (hotpla  test) and paw 
he t lodyni  (hotpla  test), mechanical hyper-
algesia (pin prick test), cold allodyni  (acetone 
tes ), tail cold-h peralgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Eth nol-i duced fiber derange-
m nt, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induc d Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, i OS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
S allest
gastrocnemius muscle atr phy
Dark melatonin
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T ble 2. Effects of curcumin n alcoho ic europathy, ch mothe apy-induced peripheral neuropathy (CIPN), a d diabetic painful neuropathy (DPN). 
Animals (Sex, 
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ration of Tre tme t 
Effects 
Reference 






Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e.,
twice daily), oral, 10 weeks + cu cumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyper lgesia thr sh ld (Randall–
Selitto p w p ssur  test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
c lcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcum n per se: 60 mg/kg, i.p. 10 week  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
cu cumin (30 and 6 oral, 10 w ks)  
Silden fil per s : 
10 mg/kg, i.p. 10 week  
35% (v/v) etha ol (10 / , twice d ily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) eth nol (10 g/kg, twice daily, ral, 10 
weeks) + curcumin (30 mg/k , oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Co bination ✓ I pr ved motor coordination 
(rotarod test) 
↓  Thermal hyperalgesia (hotplate test) nd p w 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
t st), tail cold-hyperalgesia (tail immersion test) 
Not tested 
MDA level  
✓ GSH l v l
↓  Ethanol-indu ed fiber derange-
ment, nerve fiber sw lling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
P clitaxel (  mg/kg, i.p., 5 c nsecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 cons cutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciati  nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expression  of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alc h lic neuro athy, che otherapy-induce  peripheral neuropathy (CIPN), an diabetic painful neuropathy (DPN).
Animals (Sex, 
Strain)  
Dose (mg/kg), Route of Administration, Du-






Histopath logic l/ 
Biochemical/Molecular 
Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e.,
twice daily), oral, 10 weeks + cu cumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical yperalgesia thresh ld (Randall–
Selitto paw p essur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium cont   
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either s x 
Curcum n per s : 60 mg/kg, i.p. 10 eeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
cu cumin (30 an  6 oral, 10 w eks)  
Silde fil p r s :
10 m /kg, .p. 10 weeks 
35% (v/v) ethanol (10 g/k , twice d ily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks) 
35% (v/v) ethanol (10 g/kg, tw ce daily, oral, 10 
weeks) + curcu in (30 g/kg, oral 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Im roved motor c ordinatio  
(rot rod test) 
↓  Thermal hy eralgesia (hotpla test) a d p w 
he t allodynia (hotpla  test), mech nical hyper-
algesia (pin prick test), cold allodyni  (acetone 
t s ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel
✓ GSH l vel
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling,
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (  , i.p., 5 c nsecutive days)  
Curcumin (200 mg/k day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 cons cutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc ati  nerve 
tissues:  
↓  NF-κB a d GFAP l vels  
↓  mRNA expression of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




Light and dark curcumin
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Table 2. Effects of curcumin on alcoholic neuropathy, chemotherapy-i uced peripheral neuropathy (CIPN), and diabetic painful neuropathy (DPN). 
Animals (Sex, 
Strain)  
Dose (mg/kg), Route of Administration, Du-








Alcoho ic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
n l (10 g/kg), r l, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesi  (Tail immersion test) 
X Reduc ion in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wist r Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
we ks) + ldenafi   
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, or l, 10 
we ks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Comb nat on ✓ Improved motor coordinatio  
(rotaro  test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail im ersio  test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral N uropathy (CIPN) 
Mal  Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 con ecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alcoh lic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), an  diabetic painful neuropathy (DPN). 
Animals (Sex, 
Strain)  
Dose (mg/kg), Route of Administration, Du-








Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
n l (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressur  test) 
↓ Mechanic  allodynia (von Frey hair test) 
The mal hyperalgesi  (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albi o rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice da ly, oral, 10
weeks) + curcumin (30 mg/kg, oral, 10 weeks) +
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coor i ation 
(rotaro  test)  
↓  Thermal hyperalgesia (hotpla  test) and paw 
he t allodynia (hotpla  test), mechanical hyper-
algesia (pin prick test), cold allodyni  (aceton  
tes ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral N uropathy (CIPN) 
Mal  Spr gue-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested ot tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Tab e 2. Effects of curcumin on alcoho ic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic painful neuropathy (DPN). 
Ani als (Sex, 
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Dose (mg/kg), Route of Administration, Du-









Male Wistar ra s 
35% (v/v) ethanol 10 g/kg, b.i.d (bi  in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 week  + 35% (v/v) tha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyp ralgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reductio  in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  





of either sex 
Curcumin per s : 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, ral, 10 weeks)  
Sild nafil per se: 
10 mg/kg, i.p. 10 we ks 
35% (v/v) eth nol (10 g/ g, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curc min (30 mg/kg, oral, 10 weeks) + 
s ldenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Spragu -
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alcoholic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), an  diabetic painful neuropathy (DPN). 
Animals (Sex, 
Strain)  
Dose (mg/kg), Rout  of Administration, Du-








Alc holic Neuropathy 
Male Wi tar ra s 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 w eks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalge ia threshold (Randall–
Selitto paw pressur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albi o rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i. . 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, or l, 10 
weeks) + silde afil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotpla  test) and paw 
he t allodynia (hotpla  test), mechanical yper-
algesia (pin prick test), cold allodyni  (acetone 
tes ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Higher
color intensity of nerve myelin s ining
(Luxol Fast Blue staini g)
Dark melatonin
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Table 2. Effects of curcumin on alcoholic n uropathy, chemotherapy-induced peripheral neur pathy (CIPN), and diabetic painful neur thy (DPN). 
Animals (Sex, 
Strai )  
Dose (mg/kg), Route of Adminis rati n, Du-








Al ohol  Neur pat y 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twi  daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, or l, 10 w eks + 35% (v/v) etha-
ol (10 g/kg), or l, 10 we ks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X R duction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per s : 60 mg/kg, .p. 10 w eks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumi  (30 a d 60 mg/kg, oral, 10 eeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) et an l (10 g/kg, twice daily, oral, 10 
weeks) + ildenafil  
(5 a d 10 mg/kg, r l, 10 weeks)  
35% (v/v) et no (10 /kg, tw ce daily, oral, 10 
weeks) + curcum n 30 m /kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 we ks) 
Co bination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw
heat ll dy ia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (ac ton  
est), tail cold-hyperalgesia (tail immersion te t)
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 co secutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclit xel (2 mg/kg, i.p., 5 consecutive days) + 
ur min (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of curcumin on alcoholi  neuropathy, chemotherapy-i duced peripheral neuropathy (CIPN), n  diab tic painful neur thy (DPN). 
Ani als (Sex, 
Strain)  
Dose (mg/kg), Route of Admin stration, Du-








Alc holic Neur pathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twi e d ily), o l, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, or l, 10 we ks + 35% (v/v) etha-
ol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Ran all–
Selitto paw pressur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X R ductio in MNCV 
↓  MDA, neural n rite, and total 
calcium content  
↓  TNF-α and IL-1β  




W star Albino rats 
of e the  sex 
Curcumin per s : 60 mg/kg, .p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
cu cumin (30 an  60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, wice d ily, oral, 10 
weeks) + ild n fil  
(5 and 10 mg/kg, or l, 10 weeks)  
35% (v/v) t n l 10 g/kg, tw ce daily, oral, 10 
weeks) + curcum n 30 mg/kg, oral, 10 weeks) + 
sild nafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotpla  test) and paw 
he t ll dynia (hotpla  test), mechanical hyper-
algesia (pin prick test), cold allody i  (ac ton  
es ), tail cold-hyperalgesia (tail i mersion te t) 
Not te ted 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 g/kg, i. ., 5 co secutive days) 
Curcumin (200 mg/kg/day, oral, 10 consecutive 
ays)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
cur min (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




Light and dark curcumin
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Table 2. Effects of curcumin on lcoholic n uropathy, chemotherapy-i uc d peri heral neuropathy (CIPN), and diabetic painful neuropathy (DPN). 
Animals (Sex, 
Stra n)  
Do e (mg/kg), Rout  of Administration, Du-









Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), or , 10 we ks + cu cumi : 20, 40 
and 80 mg/kg, ora , 10 week  + 35% (v/v) etha-
nol (10 g/k ), oral, 10 w eks 
↑  Me hanical hyperalgesia t reshold (Randall–
S litto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Therm l hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, eural nitrite, and total 
calcium content 
↓  TNF-α and IL-1β  




Wi tar Albino r t  
of ith r sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35  (v/v) et a l (10 /k , t ice ail , ral, 10 
w ks) + 
curcu in (30 and 60 m /kg, oral, 10 weeks)  
S ldenafil er s : 
10 g/kg, i. . 10 weeks 
35% (v/v) e hanol (10 g/k , twi  daily, oral, 10 
wee s) + l en fil  
(5 nd 10 g/kg, ra 10 eeks) 
35% (v/v) e han l (10 g/k t i d y, o , 10 
w eks) + curcumin (30 mg/kg, or l, 10 we ks) + 
sildenafil (5 mg/k , or l, 10 weeks)
Combination ✓ Improv d motor coordination 
(rotarod est)  
↓  The mal hyperalgesi  (hotplate tes ) and paw 
he t allodynia (hotpl te test), cha ic l hyper-
algesia (pin prick test), col  allodynia ( c tone 
st), tail cold-hyperalgesia (tail immersion t st) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Etha ol-induced f ber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitax l (2 mg/kg, i.p., 5 consecutiv  d ys)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested
In spi l cord and sciatic nerve 
tissues:  
↓  F-κ  and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, NOS, Bcl-2 and Bcl-
xL 
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects f curcumin on alcoholic neuropathy, chemoth rapy-induced peripheral neuropathy (CIPN), an  diabetic painful neuropathy (DPN). 
Animals (Sex, 
Strai )  
Dose (mg/kg), Rout  of Administration, Du-








A c holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), or , 10 e ks + curcumin: 20, 40 
and 80 mg/kg, ora , 10 we k  + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks
↑  Me hanical hyperalg sia t eshold (Randall–
S litto paw pre sur  test) 
↓  M chanic  allodynia (von Frey hair test) 
T rmal hyper lgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, eural n rite, and total
calcium content 
↓  TNF-α and IL-1β  




Wi tar Albin  rats 
of ither sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35  (v/v) e a l (10 / , t ice ail , ral, 10 
we ks) + 
curcu in (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 g/kg, i.p. 10 weeks 
35% (v/v) e hanol (10 g/kg, twi  daily, oral, 10
weeks) + il enafil
(5 nd 10 mg/kg oral, 10 weeks)  
35% (v/v) eth n l (10 g/k , twic  d ily, oral, 10 
weeks) + curcumin (30 mg/kg, or l, 10 we ks) + 
sildenafil (5 mg/kg, or l, 10 we ks) 
Combination ✓ Improv d motor coordination 
(rotarod test)  
↓ The mal hyperalgesia (hotpla  test) and paw 
he t allodynia (hotpla test), mechani l hyper-
algesia (pin p ick test), col  allodyni ( c tone 
t s ), tail cold-hyperalgesia (t il i mersio  test) 
Not tested 
↓  MDA l v l  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, n ve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprag e-
D wley rats 
Paclitaxel (2 mg/kg, i.p., 5 consec tive d s)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested ot tested 
In spi al cord and sc atic nerve 
tissues:  
↓  F-κ  and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, NOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Hi her
umber of Schwann c lls
Light curcumin
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Table 2. Effects of curcumin on alcoholic neurop thy, chem t rapy-induce  periph ral neuropathy (CIPN), d diabetic painful n uropathy (DPN). 
Anim s (Sex, 
S rain)  
Dose (mg/kg), Route of A ministration, Du-









Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in di , i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (T il immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  
and DNA fragmentation in sciatic 
nerve 
[80] 
Combi ation Study 
Wistar Albino rats 
of either sex 
urcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sild n fil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% ( /v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 g/kg, oral, 10 weeks) 
Combination ✓ I proved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hot late test) a  paw 
heat llodynia (hotplate test), mechanical hyper-
algesia (pin rick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIP ) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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Table 2. Effects of urcumin on alcoholic neuropathy, chemoth rapy-induced peripheral neuropathy (CIPN),  diabetic painful neurop thy (DPN). 
Animal  (Sex, 
Strai )  
Dose (mg/kg), R ute of Admi istration, Du-








Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 eeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mecha ical hyperalgesia threshold (Randall–
Selitto paw pressur  test) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail i mersion test) 
X Reductio in MNCV 
↓  MDA, neural n rite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
week ) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ I proved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hot la  test) and paw 
heat allodyni  (hotpla  test), mechanical hyper-
algesia (pin prick test), cold allodyni  (acetone 
tes ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓   expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Increase numb r
of neurofilament-posi ive stain d areas
Dark el tonin
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T ble . Effects of urcu in on alc holic n uropathy, chemother p -i du d peripheral neur athy (CIPN), and diabetic painful neurop thy (DPN). 
Anim ls (Sex, 
Strain)  
Dose (mg/kg), Route of Administratio , u-









Male Wistar rats 
35% (v v) eth nol 10 g/ g, b.i.d (bis in die, i.e.,
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mech nical h peralgesia thres old (Randall–
Selitto p w pressu  tes ) 
↓  M chanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
 MDA, neural nitrite, and total 
calcium c tent  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin p r s : 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 /kg, twice daily, oral, 10 
weeks) +
curcumin (30 and 6 mg/ g, oral, 10 weeks)  
Sildenafil er se: 
10 g/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twic  daily, oral, 10 
weeks) + sildenafil  
(5 a d 1  / , r l,  s) 
35% (v/v) ethanol (10 / t ice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Co bination ✓ I prov d mo or coordination 
(ro arod test)  
↓  Thermal hyp ralgesia (hotpl te t st) and paw 
he t allo nia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Eth ol-induced fiber derange-
ment, n rve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 con ecutive 
days) 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tis ues: 
↓  NF-κB and GFAP levels  
↓  mRNA e pressions of TNF-α, 
IL6, F-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRN  ex ression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
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T ble 2. E fects of ur u i  on alcohol  n uropathy, chemoth rap -indu ed peripheral n uropathy (CIPN), an  diabetic painful neuropathy (DPN). 
Animals (Sex, 
Strain)  
Dos  (mg/kg), Route of Administration, Du-








Alc holic Neuropathy 
Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e.,
twice daily), oral, 10 we ks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mech nical h peralgesia t reshold (Randall–
Selitto paw pressu  tes ) 
↓  Mechanic  allodynia (von Frey hair test) 
Thermal hyperalgesi  (Tail i mersion test) 
X Reductio in MNCV 
 MDA, neural n rite, and total 
calc um co tent  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Curcumin p r se: 60 mg/kg, i.p. 10 eeks 
35% (v/v) ethanol (10 /kg, twic  daily, oral, 10 
weeks) + 
curcu in (30 and 6 mg/ g, oral, 10 weeks)  
Sildenafil per se: 
10 g/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 a d 1  / , r l,  s) 
35% (v/v) ethanol (10 / , t ice daily, oral, 10 
weeks) + c rcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combin tion ✓ Im rove  mo or coordin tion 
(rotarod test)  
↓  Ther al hyperalgesia (hotpl  t st) and paw 
he t allod nia (hotpl  test), mechanical hyper-
algesia (pin prick test), cold allodyni  (acetone 
tes ), tail cold-hyperalgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
 GSH l vel 
↓  Ethanol-induced fiber derange-
m nt, n rve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
s) 
Paclitax l (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tis ues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRN  expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Bett r
n urofilament-positive stained ar as
[151]
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Table 4. Cont.







Spared Nerve Injury (SNI)
Male Sprague-Dawley rats
SNI + curcumin (100 mg/kg, i.p., 4 weeks)
SNI + PI3K inhibitor LY294002 (30 mg/kg,
i.p., 10 min before curcumin administration)
+ curcumin (100 mg/kg, i.p., 4 weeks)
SNI + siNGF (1ng in 5µL, i.t., 10 min before
curcumin administration) + curcumin
(100 mg/kg, i.p., 4 weeks)
In vitro: 30 mM
Not tested Not tested
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Table 2. Effects of curcumin on alcoholic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic painful neuropathy (DPN). 
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Male Wistar rats 
35% (v/v) ethanol 10 g/kg, b.i.d (bis in die, i.e., 
twice daily), oral, 10 weeks + curcumin: 20, 40 
and 80 mg/kg, oral, 10 weeks + 35% (v/v) etha-
nol (10 g/kg), oral, 10 weeks 
↑  Mechanical hyperalgesia threshold (Randall–
Selitto paw pressure test) 
↓  Mechanical allodynia (von Frey hair test) 
Thermal hyperalgesia (Tail immersion test) 
X Reduction in MNCV 
↓  MDA, neural nitrite, and total 
calcium content  
↓  TNF-α and IL-1β  




Wistar Albino rats 
of either sex 
Cu cumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
curcumin (30 and 60 mg/kg, oral, 10 weeks)  
Sildenafil per se: 
10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
PC-12 neurons against H2O2-induced
apopt sis by ↑ TrkA, Akt and ↓ p17
↓ pro-NGF but ↑mature NGF level
PI3K/Akt inhibition ↑ Apoptotic rate by
decreasing p17, Ki67, and cyclin D1
NGF suppression and PI3K inhibition ↑
Neuron cell death by increasing proNGF




SNI or sham + curcumin (30, 60, 120 mg/kg,
i.p., twice daily from day 1 until day 7
after surgery)
↓Mechanical (von Frey) and cold
(acetone test) allodynia Not tested
X IL-1β protein level




Spinal Nerve Ligation (SNL)
Female Wistar rats
SNL or sham + curcumin (30,
100, 200, and 300 µg, i.t., 14 days
after surgery)
SNL or sham + curcumin (10, 100,












SNL + curcumin (200 µg, i.t., 7th, 8th, 9th,
10th, 15th, and 20th day after surgery)
↓ SNL-induced mechanical
allodynia (von Frey) from 10th
day post-treatment
Not tested Not tested [161]
Behavioral modalities are mentioned within parentheses.
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Combination ✓ Improved motor coordination 
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↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
= protect/i proved;
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Co bination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
h a  allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
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[83] 
Ch motherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats
Pa litaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Pa litaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
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↑  mRNA expression of Nrf2  
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3, p53, Apaf-1 
[84] 
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[80] 
Combinatio  Study 
Wistar Albino rats 
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Curcumin per se: 60 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + 
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10 mg/kg, i.p. 10 weeks 
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sild nafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotpla  test) and paw 
he t allodyni  ( otpla  test), mechanical hyper-
algesia (p n prick test), cold allodyni  (acetone 
tes ), tail cold-hyp ralgesia (tail i mersion test) 
Not tested 
↓  MDA l vel  
✓ GSH l vel 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sc atic nerve 
tissues:  
↓  NF-κB and GFAP l vels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
= exert/induce; ↑ = increase/upregulate; ↓ = decrease/downregulate; O = no difference; X = prevented/inhibited; CMAP =
compound muscle action potential; DRG = dor al root gangli n; H2O2 = hydrogen peroxide; IL-1β = interleukin-1β; i.p. = intraperitoneal; i.t. = intrathecal; JAK2-STAT3 = Janus kinase 2-signal transducer and
activator of tran cription 3; MNCV = motor nerv conduction v locity; MPZ = my lin protein zero; NALP1 = NAcht leucine-rich-repeat protein 1; NCV = nerve con uction velocity; NGF = nerve growth factor;
Nrf2 = nuclear factor erythroid 2–related factor 2; PI3K/Akt = phosphatidylinositol 3-kinase/Akt protein kinase B; PMP22 = peripheral myelin protein 22; ROS = reactive oxygen species; SFI = sciatic functional
index; SNC = sciatic nerve crush; SNCV = sensitive nerve conduction velocity; SNI = spared nerve injury; SNL = spinal nerve ligation; TrkA = tropomyosin receptor kinase A.
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4.5.2. Spared Nerve Injury (SNI)
SNI model resembles the stimulus-evoked pain that is observed under clinical set-
tings of neuropathic pain syndrome [162,163]. Table 4 summarizes the effects of curcumin
on SNI. Curcumin reduced SNI-induced neuropathic pain behaviors by activating ei-
ther the tropomyosin receptor kinase A (TrkA) and phosphatidylinositol 3-kinase/Akt
protein kinase B (PI3K/Akt) cell survival signaling pathway [158] or the Janus kinase
2-signal transducer and activator of transcription 3 (JAK2-STAT3) signaling pathway [159].
Nerve damage induces neuroinflammation [164], which leads to the upregulation of pro-
inflammatory cytokines [164], including IL-1β, that contribute to the development and
maintenance of neuropathic pain [165]. Curcumin downregulated the production of ma-
ture IL-1β in the spinal cord and thus attenuated SNI-induced neuropathic pain [159].
Furthermore, curcumin induced the anti-allodynic activity by inhibiting the NAcht leucine-
rich-repeat protein 1 (NALP1) inflammasome and activating the JAK2-STAT3 pathway
in astrocytes [159]. On the other hand, curcumin demonstrated protective effects against
injured neurons by stimulating the release of nerve growth factor (NGF) and further
activating the TrkA and PI3K/Akt cell survival signaling pathway [158].
4.5.3. Spinal Nerve Ligation (SNL)
Kiso et al. [166] developed a L5/L6 mice spinal nerve ligation model, which is em-
ployed in studying neuropathic pain. In this nerve ligation model, mechanical allodynia
develops at day 1 and lasts for two months after the surgery.
Table 4 summarizes the effects of curcumin on SNL. Lee et al. [161] reported that
intrathecal administration of curcumin alleviated SNL-induced allodynia, but they did
not explore the underlying mechanisms of action. On the other hand, Pastrana-Quintos
et al. [160] reported that both oral and intrathecal curcumin induced anti-allodynic activity
in an SNL model of neuropathic pain and that the anti-allodynic effect was mediated via the
nitric oxide-cyclic guanosine monophosphate-adenosine triphosphate-sensitive potassium
+ channels pathway. Furthermore, the highest dose of oral (310 mg/kg) and intrathecal
(0.3 mg) curcumin exerted maximal anti-allodynic effects, and intrathecal curcumin even
produced significantly higher anti-allodynic activity compared to gabapentin [160].
5. Curcumin and Postoperative Pain and Preemptive Analgesia—Preclinical Studies
5.1. Postoperative Pain
Patients perceive postoperative pain as one of the most noxious aspects of surgical
pain for which effective control measures are lacking [167–169]. Table 5 summarizes the
effects of curcumin on postoperative pain and preemptive analgesia. Acute treatment of
curcumin demonstrated anti-hyperalgesic activity by dose-dependently reversing mechan-
ical hyperalgesia, whereas repeated treatment facilitated the recovery of postoperative
pain [170]. However, repeated treatment before surgery did not exert impact on the preven-
tion or reduction in postoperative pain [170]. The results emphasize that acute curcumin
treatment may be useful in treating postoperative pain. Curcumin also exerted its analgesic
activity by alleviating incision-induced inflammation, spontaneous pain, functional gait
abnormalities, and hyperalgesic priming [171]. Although curcumin did not alter the pro- or
anti-inflammatory cytokines at the peri incisional level, it augmented transforming growth
factor-β (TGF-β), which is implicated to inhibit nociception in both inflammatory and neu-
ropathic pain models [172]. Ju et al. [173] provided important insights into the underlying
mechanisms of the antinociceptive activity of curcumin in postoperative pain. The results
showed that antagonizing the gamma-aminobutyric acid (GABA) receptors abrogated the
curcumin-induced anti-hyperalgesic activity, and curcumin treatment elevated the mRNA
expression of GABA-A and GABA-B in the incised spinal cord. On the other hand, antago-
nizing the opioid receptors reversed the anti-hyperalgesic activity of curcumin but did not
alter the mRNA expression of opioid receptors in the spinal cord, indicating the indirect
involvement of opioid receptors in mediating curcumin antinociception of postoperative
pain [173]. Together, the findings conclude that spinal GABA receptors are important in
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modulating postoperative pain and that curcumin increases the synthesis of GABA mRNA
in the spinal cord, thus mediating the antinociception of postoperative pain. Therefore,
postoperative pain can be treated or prevented with spinal GABA receptor agonists.
Table 5. Effects of curcumin on postoperative and preemptive analgesia.






Male Sprague-Dawley rats Incision + curcumin (0.01, 0.03,or 0.1 mg, i.t.)
↓Mechanical hypersensitivity (von Frey)
Antagonists GABA-A (bicuculline) and
GABA-B (saclofen) X
antinociceptive activity
Antagonists mu (CTOP), delta
(naltrindole), and kappa (GNTI) opioid
receptor X antinociceptive activity
↑mRNA expressions of
GABA-A and GABA-B in
incised spinal cord
O mRNA expressions of
opioid receptors in incised
spinal cord
[173]
Male C57BL/6 mice Incision + curcumin (50 mg/kg, i.p.,4 days)





O Paw edema (laser sensor technique)
and hindpaw temperature (fine
wire thermocouple)
O Morphine-induced place preference
(affective component of incision
measured by conditioned CPP)
X Functional abnormalities in gait indices
(gait analysis)









Acute treatment: Incision + curcumin
(10–40 mg/kg, oral, 1 day after surgery)
Repeated treatment: Incision + curcumin
(10–40 mg/kg, oral, 20 min before to
surgery and twice daily for 7 days)
Repeated treatment before surgery:
Curcumin (10–40 mg/kg, oral, twice
daily for 7 days before surgery) + incision
Acute treatment ↓Mechanical
hyperalgesia (von Frey)
Repeated treatment before surgery O
Mechanical hyperalgesia
Repeated treatment
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Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, i OS, Bcl-2 and Bcl-
L  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-




Repeated treatment before surgery O
recovery rate




Curcumin [(130 mg/kg, oral, 3 days prior
to CPB and extracorporeal
support surgery
Not tested ↓ Concentrations of IL-6,TNF-α, and ICAM-1 [174]
Male Wistar Bratislava
Albino rats
Nitroglycerin (NTG) (1 mg/100 g body
weight i.p.) + curcumin (10 mg/100 g
body weight, i.p., 14 days before
NTG administration)
↓ Number of flinches and shakes
(formalin test)
↓ Blood pressure




Female Wistar Albino rats Curcumin (400 mg/kg, oral, 45 minbefore formalin injection)
↓ Thermal pain (hotplate test)
↓ Number of flinches (formalin test) Not tested [176]
Behavioral modalities are mentioned within parentheses.
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Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
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[84] 
= improve, facilitate; ↓ = alleviate/decrease/attenuate; O = no effects/no
alteration; X = abrogate/prevent; CPB = cardiopulmonary bypass; CPP = conditioned placed preference; GABA = gamma-Aminobutyric
acid; ICAM-1 = intercellular adhesion molecule 1; IL-1β = int leukin-1β; IL-6 = interleukin 6; i.p. = intraperitoneal; i.t. = intrathecal; MDA
= malondialdehyde; mRNA = messenger RNA; TAC = total antioxidative capacity; TGF-β = transforming growth factorβ; TNF-α = tumor
necrosis factor alpha; TOS = total oxidative status.
5.2. Preemptive Analgesia
Preemptive analgesia is an antinociceptive treatment that is applied to prevent altered
processing of the afferent input that amplifies postoperative pain by preventing central
sensitization caused by incisional and inflammatory injuries, and it covers both the period
of surgery and the initial postoperative period. The nature of surgery determines the
balance between incisional injury and inflammatory injury, with inflammatio injury being
a dominant factor [177,178]. The application of preemptive analgesia is more effective in
redu ing surgery-induced nociceptive pain transmission when compared to the application
of analgesic treatment provided after surgery [179].
Nurullahoglu et al. [176] suggested the preemptive analgesic effects of curcumin on
acute thermal and inflammation-induced pain in female Wistar Albino rats. Furthermo ,
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the study compared the preemptive effects of curcumin with intraperitoneal administration
of diclofenac (10 mg/kg), a non-steroidal anti-inflammatory drug [180]. Diclofenac exerts
controversial preemptive effects, with some studies, showing no differences in the effects in
between pre- and postoperative diclofenac-treated patients undergoing laparoscopic tubal
ligation [177], while other studies reported that preoperative administration of diclofenac
along with ketorolac and piroxicam reduced postoperative pain in patients undergoing
laparoscopy [181,182]. Based on Nurullahoglu et al.’s [176] study, both curcumin and
diclofenac exerted preemptive analgesic effects. Bulboacs et al. [175] demonstrated the
preemptive effects of curcumin in a rodent migraine model. Curcumin induced analgesic
effects in both phase I dominated by vasodilation and phase II dominated by inflammation
of formalin test [175]. Moreover, curcumin reduced oxidative stress markers and blood
pressure and increased TAC. The study also compared the preemptive analgesic effects of
curcumin with a beta-1 blocker, propranolol [183], which is effective in treating migraine
patients by increasing the temporal distances between migraine attacks [184]. Another drug,
indomethacin, exerts antimigraine effects due to its antinociceptive and anti-inflammatory
properties [185]. Bulboacs et al. [175] demonstrated that curcumin had superior activity
as compared to propranolol- and indomethacin-treated groups, indicating that curcumin
could be used as prophylaxis for migraine. In addition to rodent models, the preemptive
analgesic property of curcumin was also effective in a swine model of cardiopulmonary
bypass (CPB) and extracorporeal support, resulting in a decrease in TNF-α and intercellular
adhesion molecule (ICAM-1) expressions [174]. This study in a swine model provides data
for the development of a human translational study [174]. However, further studies are
needed to explore the underlying mechanisms of preemptive analgesic effects of curcumin.
6. Curcumin Formulations and Neuropathic Pain—Preclinical Studies
Preclinical and clinical studies have employed different curcumin formulations syn-
thesized in order to improve the solubility, bioavailability, and pharmacokinetics of cur-
cumin [186–190].For example, in a clinical study, a novel bio-enhanced preparation of
curcumin called BCM-95CG (Biocurcumax) showed 6.93- and 6.3-fold higher bioavailability
when compared to curcumin and a curcumin-lecithin-piperine formula, respectively [186].
However, Shoba et al. [189] reported that concomitant administration of piperine enhanced
the bioavailability, absorption, and serum concentration of curcumin in both rodents and
humans with no side effects. Another curcumin formula, Theracurmin, which is curcumin
dispersed with colloidal submicron particles, exhibited higher absorption efficiency com-
pared to other curcumin drug-delivery systems, such as BCM-95 (micronized curcumin
with turmeric essential oils) and Meriva (curcumin-phospholipid) [187]. A curcumin
formulation with a combination of hydrophilic carrier, cellulosic derivatives, and natu-
ral antioxidants further showed higher absorption in blood compared to unformulated
curcumin [188].
However, only a few studies have looked into the effects of curcumin formulations
in neuropathic pain, specifically diabetic and CCI-induced neuropathies [27–34] (Figure 3).
Table 6 summarizes the effects of different curcumin formulations on neuropathic pain.
Curcumin derivative J147 was reported to possess potent neurogenic and neuroprotective
activities and was initially developed to treat neurodegenerative conditions [191,192]. J147
exerted its therapeutic potential by reducing multiple pathogenic pathways associated with
the DPN in rodent models [27,33]. Reduced AMP kinase signaling is known to be associ-
ated with DPN [193,194]. J147 stimulated the AMPK signaling pathway by increasing its
protein and mRNA expressions [27,33]. J147 also ameliorated diabetes-induced mechanical
hypersensitivity [27,33], heat hypersensitivity [27], and increased MNCV [27]. Curcumin
delivery systems, such as the self-nano emulsifying drug delivery system (SNEDDS) [30]
and nanoparticle-encapsulated curcumin (curcumin-polybutylcyanoacrylate nanoparticle-
encapsulated particles: PEGMA-DMAEMA-MAO) [28] improved diabetes-induced mechani-
cal and thermal hypersensitivities [28,30]. The nanoparticle-encapsulated curcumin decreased
the mRNA and protein expressions of purinergic receptor 12 (P2Y12), which is expressed on
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satellite glial cells (SGCs) in DRG [195,196]. P2Y12 is activated by ATP and ADP and plays
an important role in transmitting painful signaling [195,197–199]. The decreased expression
of P2Y12 by nanoparticle-encapsulated curcumin led to the decrease in pro-inflammatory
cytokines IL-1β and connexin 43 (Cx43) and ultimately decreased neuronal excitability in
the DRG and resulted in attenuation of diabetes-induced painful behavior [28]. Furthermore,
SNEDDS more efficiently reversed diabetes-induced functional, sensorimotor, and biochemi-
cal deficits by decreasing neuroinflammation and improving the antioxidative defense system
as compared to naïve curcumin [30]. Besides diabetes, curcumin formulae are also effective in
attenuating CCI-induced neuropathic pain by decreasing pronociceptive peptides [161] or
pro-inflammatory cytokines [32]. A curcumin formula, curcumin-loaded poly (d, l-lactide-co-
glycolide) nanovesicles (PLGA-CUR), at both low and high doses, attenuated CCI-induced
pain behaviors [34]. The results further confirm the better efficacy of curcumin formulations
over parent curcumin, which possesses poor bioavailability and is required at high doses to
attenuate neuropathic pain.
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 24 of 36 
 
 
3). Table 6 summarizes the effects of different curcumin formulations on neuropathic pain. 
Curcumin derivative J147 was reported to possess potent neurogenic and neuroprotective 
activities and was initially developed to treat neurodegenerative conditions [191,192]. J147 
exerted its therapeutic potential by reducing multiple pathogenic pathways associated 
with the DPN in rodent models [27,33]. Reduced AMP kinase signaling is known to be 
associated with DPN [193,194]. J147 stimulated the AMPK signaling pathway by increas-
ing its protein and mRNA expressions [27,33]. J147 also ameliorated diabetes-induced me-
chanical hypersensitivity [27,33], heat hypersensitivity [27], and increased MNCV [27]. 
Curcumin delivery systems, such as the self-nano emulsifying drug delivery system 
(SNEDDS) [30] and nanoparticle-encapsulated curcumin (curcumin-polybutylcyanoacry-
late nanoparticle-encapsulated particles: PEGMA-DMAEMA-MAO) [28] improved dia-
betes-induced mechanical and thermal hypersensitivities [28,30]. The nanoparticle-encap-
sulated curcumin decreased the mRNA and protein expressions of purinergic receptor 12 
(P2Y12), which is expressed on satellite glial cells (SGCs) in DRG [195,196]. P2Y12 is acti-
vated by ATP and ADP and plays an important role in transmitting painful signaling 
[195,197–199]. The decreased expression of P2Y12 by nanoparticle-encapsulated curcumin 
led to the decrease in pro-inflammatory cytokines IL-1β and connexin 43 (Cx43) and ulti-
mately decreased neuronal excitability in the DRG and resulted in attenuation of diabetes-
induced painful behavior [28]. Furthermore, SNEDDS more efficiently reversed diabetes-
induced functional, sensorimotor, and biochemical deficits by decreasing neuroinflamma-
tion and improving the antioxidative defense system as compared t  naïve curcumin [30]. 
Besides diabetes, curcumin formula  are also effe tive in attenuating CCI-indu ed neuro-
pathic pain by decreasing pronociceptive peptides [161] or pro-inflammatory cytokines 
[32]. A curcumin formula, curcumin-loaded poly (d, l-lactide-co-glycolide) nanovesicles 
(PLGA-CUR), at both low and high doses, attenuated CCI-induced pain behaviors [34]. 
The results further confirm the better efficacy of curcumin f rmulations over parent cur-
cumin, which possesses poor bioavailability and is required at high doses to attenuate 
neuropathic pain. 
 
Figure 3. Schematic representations of different curcumin formulations and delivery systems along with their respective 
examples discussed in the review (created with BioRender). 
Figure 3. Schematic representations of different curcumin formulations and delivery systems along with their respective
examples discussed in the review (created with BioRender).
Together, the efficacy of these curcumin formulations against neuropathic pain sup-
ports their applications in clinical investigation. Eventually, further improvement of
curcumin formulations would enhance their use as adjuvants to neuropathic drugs.
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Table 6. Effects of different curcumin formulations on neuropathic pain.










Female Swiss Webster mice or
diabetic rats (strain and sex were
not specified)
STZ − 90 mg/kg, i.p.
STZ + phenyl hydrazide derivative J147
(10, 50 mg/kg, i.p. oral, 20 weeks)
↓ Blood glucose and HbA1c levels
↑ Paw thermal response (Hargreaves test)
↓ Tactile allodynia (von Frey)
O Sensorimotor function (rotarod test)
↓MNCV
↓ TNFR1, TNFR2, and type I diabetes mellitus
signaling pathways
↑ AMPK, and ephrin receptor
signaling pathways
↓ Protein levels of
TNF-α, TSPO, iNOS or GFAP and peripheral
inflammation marker C-reactive protein
[27]
Male SPF rats
STZ − 50 mg/kg, i.p.
STZ + J147 (10 or 100 µM of at 10 mg/kg
weight, 5 days)
In vitro: J147 (10 and 100 µM)
↓Mechanical withdrawal threshold
(von Frey)
O Cell viability and apoptosis of RSC96
cells
↑ AMPK mRNA and protein expression levels
↓ TRPA1 mRNA and protein expression levels





STZ − 30 mg/kg, i.p.
STZ + nanoparticle-encapsulated
curcumin, 16 mg/kg, sublingual vein, 7th,
and 8th week
↓Mechanical (electronic mechanical
stimulator) and thermal (thermal paw
stimulator) hyperalgesia
Interacted perfectly with P2Y12 receptor
agonist-binding pocket
↓mRNA and protein expressions of P2Y12 in
DRG
↓ Co-localization of glutamine synthetase (a
marker of SGCs) in DRG
↓mRNA and protein expression of IL-1β and
Cx43 expressions in DRG
X AKT activation
[28]
Self-Nano Emulsifying Drug Delivery System (SNEDDS) Curcumin
Male Sprague–Dawley rats
STZ − 55 mg/kg, i.p.
STZ + naïve curcumin (30, 100 and
300 mg/kg, oral, 2 weeks)
STZ + SNEDDS curcumin (30, 100 and
300 mg/kg, oral, 2 weeks)
O Body weight and plasma glucose level
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35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + sildenafil  
(5 and 10 mg/kg, oral, 10 weeks)  
35% (v/v) ethanol (10 g/kg, twice daily, oral, 10 
weeks) + curcumin (30 mg/kg, oral, 10 weeks) + 
sildenafil (5 mg/kg, oral, 10 weeks) 
Combination ✓ Improved motor coordination 
(rotarod test)  
↓  Thermal hyperalgesia (hotplate test) and paw 
heat allodynia (hotplate test), mechanical hyper-
algesia (pin prick test), cold allodynia (acetone 
test), tail cold-hyperalgesia (tail immersion test) 
Not tested 
↓  MDA level  
✓ GSH level 
↓  Ethanol-induced fiber derange-
ment, nerve fiber swelling, 
Schwann cells activation 
✓ Nerve fibers 
[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
3, p53, Apaf-1 
[84] 
Thermal hyperalgesia (tail flick test) in
both hot and cold immersion
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Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
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xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
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[84] 
Mechanical hyp ralgesia (von Frey
and Randall Sellitto tests)
Naïve and SNEDDS ↓
MNCV and NBF
↓MDA levels
SNEDDS ↓ NF-κB protein expression
SNEDDS X IKK-β
phosphorylation expression
SNEDDS ↓ Protein expression of NF-κB
positive cells in nerves
SNEDDS ↓ COX-2 and iNOS protein level
Naïv and SNEDDS ↓ IL-6 level in
sciatic nerves
SNEDDS ↓ TNF-a level in sciatic nerves
[30]
CCI
Curcumin (Cur) Loaded with Lipid Nanocapsules (Cur@LNCs)
Female Sprague-Dawley rats CCI + Cur@LNCs, 400 µL inject, 7 days ↓ Thermal hyperalgesia (hotplate) ↓ Sciatic nerve damages [29]
Int. J. Mol. Sci. 2021, 22, 4666 23 of 36
Table 6. Cont.








Curcumin Prodrug-Curcumin Diglutaric Acid
Male ICR mice CCI + curcumin diglutaric acid (CurDG)(25, 50, 100, and 200 mg/kg, oral, 14 days)
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[83] 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 
Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
secutive days) 
Not tested Not tested 
In spinal cord and sciatic nerve 
tissues:  
↓  NF-κB and GFAP levels  
↓  mRNA expressions of TNF-α, 
IL6, NF-κB, iNOS, Bcl-2 and Bcl-
xL  
↑  mRNA expression of Nrf2  
↓  mRNA expressions of caspase-
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[84] 
Mechanical allodynia (von Frey), and
thermal hyperalgesia (plantar test)
O Motor performance (rotarod test)
↓ Overexpression of TNF-α and IL-6 levels in
both sciatic nerve and spinal cord [32]
Curcumin-Loaded Poly (d, l-lactide-co glycolide) Nanovesicles
Male CD1 mice
CCI + curcumin (20 mg/kg, intravenous
0.0005 and 0.025 mg, i.t.)
CCI + PLGA
CUR (0.045 mg curcumin/mg of
nanoparticles, 20 mg/kg, intravenous)
CCI + PLGA
CUR (0.045 mg curcumin/mg of
nanoparticles, 0.0005 and 0.025 mg, i.t.)
Low and high PLGA-CUR, i.t. ↓
Mechanical allodynia (dynamic plantar
aesthesiometer test) and thermal
hyperalgesia (plantar test)
High curcumin, i.t. ↓ allodynia
and hyperalgesia
High PLGA-CUR, i.t. ↓ IL-1β, IL-6,TNF-α and
BDNF levels in spinal cord [34]
Curcumin Derivative
Male ICR mice
Curcumin derivative KMS4034 (10
mg/kg, i.p., 120 min post-injection)
In vitro: 10 µM KMS4034
↑Mechanical thresholds (von Frey)
X ICAP and Iheat of
TRPV1-expressing
HEK293 cells
↓ CGRP expression in lamina I–II of lumbar
dorsal horns [31]
Behavioral modalities are mentioned within parentheses.
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Male Sprague-
Dawley rats 
Paclitaxel (2 mg/kg, i.p., 5 consecutive days)  
Curcumin (200 mg/kg/day, oral, 10 consecutive 
days)  
Paclitaxel (2 mg/kg, i.p., 5 consecutive days) + 
curcumin (100 or 200 mg/kg/day, oral, 10 con-
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Not tested Not tested 
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tissues:  
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= improve; ↑ = increase; ↓ = diminish/decrease/ameliorate; O = no effects/no changes; X = block/inhibit; AMPK = AMP-activated protein kinase;
BDNF = brain-der ved n urotrophic factor; Cox-2 = cyclooxygenase-2; Cur@LNCs = curcumin (Cur) loaded with lipid nanocapsules; Cx43 = connexin 43; DRG = dorsal root ganglion; GFAP = glial fibrillary
acidic protein; ICR = institute of cancer rese rch; IL- β = interl ukin-1β; interleuki 6; iNOS = inducible nitric oxide synthase; i.p. = intraperitoneal; i.t. = intrathecal; MDA = malondialdehyde; mRNA =
messenger RNA; P2Y12 = purinergic receptor 12; PLGA-CUR = curcumin-loaded poly (d, l-lactide-co-glycolide) nanovesicles; SGC = satellite glial cells; SNEDDS = self-nano emulsifying drug delivery system;
TNF-α = tumor necrosis factor alpha; NF-κB = nuclear factor kappa B; TNFR1 = tumor necrosis factor alpha receptor 1; TNFR2 = tumor necrosis factor alpha receptor 2; TSPO = translocator protein.
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7. Curcumin and Its Formulations on Neuropathic Pain or Postoperative
Pain—Clinical Studies
A vast majority of the studies have reported the antioxidant and anti-inflammatory
properties of curcumin and its formulations in clinical settings of chronic inflammatory joint
pain, such as osteoarthritis and rheumatoid arthritis [200–208]. Only a few clinical studies
have focused on the effects of curcumin and/or its formulations in PN and postoperative
pain [209–215].
Table 7 summarizes the effects of curcumin on neuropathic pain and postoperative
pain in clinical studies. Diabetic sensorimotor polyneuropathy (DSPN) is one of the most
common complications in diabetes mellitus, resulting in impaired motor activity [216].
DSPN affects 25% of individuals with type 2 diabetes mellitus (T2DM) [217,218]. Asadi
et al. [211] reported that nano curcumin supplementation decreased the total neuropathy
score when assessed by the Toronto Clinical Neuropathy Score. The nano curcumin treat-
ment also reduced the serum levels of fasting blood glucose (FBS) and HbA1c. The study
also elucidated that DSPN can be improved by managing hyperglycemia in individuals
with T2DM. In another study, patients treated with Meriva (lecithinized curcumin) showed
significantly reduced chemotherapy-induced side effects, which was further confirmed by
the semiquantitative evaluation of chemotherapy-induced side effects in the control group.
Furthermore, patients treated with Meriva had reduced plasma levels of free radicals when
compared to the control group [212]. Curcumin is also effective against chronic PN and
pain induced by lumbar disc herniation and/or lumbar canal stenosis or carpal tunnel
syndrome [215]. A multi-ingredient formula (800 mg dexibuprofen (Dex) + Lipicur (800 mg
lipoic acid + 800 mg curcumin phytosome + 8 mg piperine), Dex + 800 mg lipoic acid, and
800 mg Dex only) reduced neuropathic pain in patients with lumbar sciatica and carpal
tunnel syndrome. Curcumin efficiently reduced the use of dexibuprofen by 40%, and
add-on therapy with lipoic acid exerted no significant results, indicating that Lipicur could
be used as an effective alternative therapeutic to treat neuropathic pain [215].
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Table 7. Effects of curcumin on neuropathic pain and postoperative pain of clinical studies.




Diabetic Sensorimotor Polyneuropathy (DSPN)
Patients with T2D (n = 80);
RCT (placebo-controlled and double-blind)
Nano curcumin (72% curcumin, 80 mg) or
placebo capsules/day for eight weeks
↓ Score of total neuropathies, reflex score, and
temperature in curcumin vs. placebo
↓ HbA1c and FBS in curcumin
vs. placebo [211]
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Patients undergoing cancer chemo- and
radiotherapy (n = 160);
RCT (placebo-controlled and double-blind)
Lecithinized curcumin (Meriva: 500 mg) or
placebo for 60 days from first cycle of chemo-
or radiotherapy
↓ Local pain rating based on VAS due to
radiotherapy in curcumin vs. placebo group
↓ Chemotherapy side effects in
curcumin vs. placebo group [212]
Peripheral Neuropathy (PN)
Patients with chronic PN and lumbar
disc herniation
and/or lumbar canal stenosis or carpal
tunnel syndrome; (n = 135);
RCT, open
Three formulations as follows: (1) Dex
(800 mg) + Lipicur [lipoic acid (800 mg) +
curcumin phytosome (800 mg) + piperine
(8 mg)]; (2) Dex + lipoic acid (800 mg) and (3)
Dex only (800 mg) capsules/day for
eight weeks
↓ Neuropathic pain in patients with lumbar
sciatica and carpal tunnel syndrome in
Lipicur group vs. others
↓ Use of Dex in the Lipicur
group vs. others [215]
Postoperative Pain
Patients undergoing oral surgery for
periodontitis (n = 15);
RCT (placebo-controlled)
Curcumin mucoadhesive film (0.5% extract)
or placebo mucoadhesive film placed on
gingiva after surgery for seven days
↓ Pain score rating and swelling in curcumin
vs. placebo group
↓ Use of oral analgesics in
postoperative period in
curcumin vs. placebo group
[210]
Patients following laparoscopic gynecologic
surgery (n = 60);
RCT, open
Curcuminoids extract (1000 mg) or standard
analgesia on postoperative days one to three
↓ VAS pain scores following surgery in
curcumin vs. standard group N/A [214]
Patients undergoing oral surgery for
impacted third molars (n = 90);
RCT (placebo-controlled)
Curcumin (200 mg) + amoxicillin (500 mg) or
control (amoxicillin 500 mg + 500 mg
mefenamic acid) three times for 24 h
↓ Pain score rating in curcumin vs.
placebo group N/A [213]
Patients undergoing laparoscopic
cholecystectomy (n = 50);
RCT (placebo-controlled and double-blind)
Curcumin (500 mg) or placebo once every six
hours/day for three weeks
↓ Pain score rating in curcumin vs.
placebo group
↓ Fatigue score and the use of
oral analgesics in
postoperative period in
curcumin vs. placebo group
[209]
↓ = Decrease/lower; CIPN = chemotherapy-induced peripheral neuropathy; Dex = dexibuprofen; DSPN = diabetic sensorimotor polyneuropathy; FBS = fasting blood glucose; HbA1c = glycated hemoglobin;
N/A = not applicable; PN = peripheral neuropathy; RCT = randomized controlled trial; T2D = type 2 diabetes; VAS = visual analog scale.
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In a pilot randomized trial, curcuminoids extracted from turmeric, containing cur-
cumin, demethoxycurcumin, and bisdemethoxycurcumin [219], reduced postoperative
pain severity after laparoscopic gynecologic surgery [214]. In another double-blinded, ran-
domized, placebo-controlled study, curcumin not only reduced postoperative pain but also
reduced fatigue based on the patient-reported outcomes following laparoscopic cholecys-
tectomy [209]. Curcumin also reduced intensity of the acute postoperative pain followed by
third molar extraction as evaluated by numeric rating scale [213]. Curcumin exerted better
efficacy in reducing orofacial pain caused by the postoperative molar extraction-induced
inflammation in comparison with mefenamic acid, a non-steroidal anti-inflammatory drug,
commonly used to treat inflammatory pain [220–222]. Postsurgical removal of the third
molar led to the upregulation of inflammatory cytokines, including interleukin 6 (IL-6) and
interleukin 8, leading to the development of inflammatory pain [223]. Therefore, in their
study, Maulina et al. [213] explained that curcumin demonstrated better anti-inflammatory
activity by directly inhibiting the inflammatory cytokines as compared to mefenamic acid
that indirectly inhibited or decreased IL-6 by suppressing the secretion of prostaglandin
E2, responsible for inducing IL-6 expression [224]. The analgesic activity of curcumin
against periodontal surgeries was further confirmed in another study in which curcumin
mucoadhesive film reduced postoperative pain and swelling over a period of one week
compared to the placebo mucoadhesive film. Therefore, the curcumin mucoadhesive
film could become a commercially available phytochemical drug delivery system in the
treatment of periodontal postsurgical pain [210]. Taken together, these aforementioned
clinical studies conclude that curcumin and its formulations could be used as adjuvants for
postoperative care.
8. Conclusions
The current review provides important information regarding the potential effects of
curcumin in treating different peripheral neuropathic conditions, including alcoholic neu-
ropathy, CCI-, CIPN-, DPN-, SNI-, and SNL-induced neuropathic and postoperative pain
(Figure 4). Based on the present review, we identified a few drawbacks in both preclinical
and clinical studies. First, only a handful studies have explored the effects of curcumin
and its formulations in neuropathic and postoperative pain under clinical settings. Future
studies should focus on conducting clinical studies on other PN pain conditions involving
curcumin. Second, in most of the clinical studies only a single dose was used. Therefore,
dose-related effects remain unknown. Third, only a few preclinical studies have compared
the antinociceptive effects of curcumin with standard drugs. In order to enhance the appli-
cation of curcumin in clinical treatment, it is important to administer clinically used drugs
as experimental controls or for a reference comparison. Fourth, most of the animal studies
evaluated the anti-hyperalgesic activity of curcumin either by monitoring the behavioral
outcomes or by measuring the biochemical paraments. Besides these two parameters, the
effects of curcumin on neuropathic pain should also be evaluated by monitoring functional
recovery and electrophysiological aspects of pain conditions. Therefore, in the future, it is
important to address the aforementioned shortcomings while designing both preclinical
and clinical studies. In conclusion, with the advent of these new formulations, including
curcuminoids, liposomal encapsulations, nanoparticles, derivatives, and analogs, the multi-
faceted favorable effects of curcumin will lead to the promising development of therapeutic
agents for treating several neuropathic and postoperative pain conditions.
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Figure 4. Effects on curcumin or its formulations at the behavior, electrophysiology/histopathology, and molecular levels in
peripheral neuropathic and postoperative pain. I. Behavior: Curcumin or its formulations inhibit or reduce DPN (1), CIPN
(2), alcoholic neuropathy (3), different peripheral injuries, such as CCI, SNC, SNI, SNL, etc., and/or postoperative pain-
induced behaviors in rodent models. Curcumin and its formulations mainly inhibit or reduce mechanical (6A), cold (6B),
heat (6C), and chemical-induced (6D) pain behaviors, as well as motor deficits (6E). II. Electrophysiology/Histopathology:
Curcumin or its formulations protect injured DRG, decrease neuronal excitability in DRG (1), resulting in attenuatio of
p inful neuropathic behavio . Curcumin or its fo ulations increase SNCV, decrease loss of DRG neurons, and i crease
diameter of nerve fibers (2). Furthermor , c rcumin and its formulations increase MNCV, decrease eurogenic lesions
(3), and atrophy of gastrocnemius muscle (4). The treatments also effectively increase myelin sheath thickness (5A) and
prevent demyelination (5B). III. Molecular: Curcumin or its formulations decrease expression of NF-κB, leading to decrease
in inflammatory proteins. Furthermore, the treatments increase expressions of Nrf2, leading to increase in levels of
antioxidative enzymes that scavenge free radicals and ultimately reduce ROS levels. Moreover, the treatments decrease
expressions of Bcl-2 and caspase-3 that lead to reduction in apoptosis and ultimately improve nerve injuries (created
with BioRender).
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